Evaluation of C-terminal Agrin Fragment as a marker of muscle wasting in patients after acute stroke during early rehabilitation. by Scherbakov, Nadja et al.
Evaluation of C-terminal Agrin Fragment as a marker
of muscle wasting in patients after acute stroke during
early rehabilitation
Nadja Scherbakov1,2, Michael Knops1, Nicole Ebner3, Miroslava Valentova3,4, Anja Sandek3, Ulrike Grittner1,
Pius Dahinden5, Stefan Hettwer5, Jörg C Schefold6, Stephan von Haehling3, Stefan D. Anker3, Michael Joebges7 &
Wolfram Doehner1,2,8*
1Center for Stroke Research CSB, Charite Universitätsmedizin Berlin, Germany; 2German Centre for Cardiovascular Research (DZHK), partner site Berlin, Germany; 3Innovative
Clinical Trials, Department of Cardiology and Pneumology, University Medicine Göttingen, Germany; 41st Department of Internal Medicine, Comenius University, Bratislava,
Slovak Republic; 5Neurotune AG, Wagistrasse 27a, Schlieren, Switzerland; 6Department of Intensive Care Medicine, Inselspital, University Hospital of Bern, Switzerland;
7Department of Neurology, Brandenburgklinik Bernau, Germany; 8Department of Cardiology, Charite Universitätsmedizin Berlin, Germany
Abstract
Background C-terminal Agrin Fragment (CAF) has been proposed as a novel biomarker for sarcopenia originating from the
degeneration of the neuromuscular junctions. In patients with stroke muscle wasting is a common observation that predicts
functional outcome. We aimed to evaluate agrin sub-fragment CAF22 as a marker of decreased muscle mass and physical
performance in the early phase after acute stroke.
Methods Patients with acute ischaemic or haemorrhagic stroke (n = 123, mean age 70 ± 11 y, body mass index BMI 27.0
± 4.9 kg/m2) admitted to inpatient rehabilitation were studied in comparison to 26 healthy controls of similar age and BMI.
Functional assessments were performed at begin (23 ± 17 days post stroke) and at the end of the structured rehabilitation pro-
gramme (49 ± 18 days post stroke) that included physical assessment, maximum hand grip strength, Rivermead motor assess-
ment, and Barthel index. Body composition was assessed by bioelectrical impedance analysis (BIA). Serum levels of CAF22
were measured by ELISA.
Results CAF22 levels were elevated in stroke patients at admission (134.3 ± 52.3 pM) and showed incomplete recovery until
discharge (118.2 ± 42.7 pM) compared to healthy controls (95.7 ± 31.8 pM, p< 0.001). Simple regression analyses revealed an
association between CAF22 levels and parameters of physical performance, hand grip strength, and phase angle, a BIA derived
measure of the muscle cellular integrity. Improvement of the handgrip strength of the paretic arm during rehabilitation was
independently related to the recovery of CAF22 serum levels only in those patients who showed increased lean mass during
the rehabilitation.
Conclusions CAF22 serum proﬁles showed a dynamic elevation and recovery in the subacute phase after acute stroke.
Further studies are needed to explore the potential of CAF22 as a serum marker to monitor the muscle status in patients after
stroke.
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Introduction
Skeletal muscle wasting has been frequently observed after
stroke.1 Already within 4 h after cerebral damage an initial
reduction of motoneurons in the musculature of paretic limb
is observed2 that persists in the chronic phase after stroke.3
Loss of muscle innervation leads to muscular weakness, inac-
tivity, and immobilization and results in muscle atrophy.
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Within the ﬁrst week after stroke muscle weakness occurs
also in the non-paretic limb.4 Decline of muscle mass has
been observed in stroke patients within ﬁrst three weeks af-
ter hemiparetic stroke.5 Further, patients who are not able to
relearn walking within 2months after stroke revealed similar
lean mass reduction in paretic and non-paretic leg.6 A combi-
nation of mechanisms, including immobilization, disuse,
inﬂammation, metabolic, and neurovegetative imbalance
after stroke, results frequently in muscle wasting and may
progress to the stroke-related sarcopenia.1,7 The presence
of stroke-speciﬁc sarcopenia has been proposed from experi-
mental8 and clinical data.9,10
Progressive degradation of muscle mass was termed as
‘sarcopenia’ and was originally observed in relationship to
aging.11 The prevalence of sarcopenia is about 5 to 10% in
persons over 65years of age.12 Numerous factors such as malnu-
trition,13 immobilization and disuse,14 hormonal imbalance etc.
are discussed in the multifactorial aetiology of sarcopenia.15–18
In aging loss of motoneurons has been proposed as pathogenic
and contributing to the developing of sarcopenia.19,20
Recently, C-terminal Agrin Fragment (CAF) has been pro-
posed as a potential marker for sarcopenia caused by degen-
eration of the neuromuscular junctions (NMJs) in elderly.21
Agrin is a heparin sulphate proteoglycan with a molecular
weight of 225 kDa, which is considered as a key organizer of
postsynaptic differentiation at NMJs.22–24 Proper clustering of
acetylcholine receptors (AChR) at post-synaptic basal lamina
depends on agrin-mediated signalling.22,25 Proteolytic cleavage
of agrin by neuronal protease neurotrypsin at NMJs triggers
inactivation and destabilization of the NMJ with subsequent
muscle degradation. A sarcopenic phenotype has been observed
in transgenic mouse with neurotrypsin overexpression.26 In
human plasma two stable and bio-inactive circulating fragments
of agrin—AgrinC110 (cleavage at α-site) and CAF22 (cleavage at
β-site) were identiﬁed (Figure 1).21 It has been shown that
elevated CAF22 plasma levels may indicate muscle wasting in
pre-frail community-dwelling older adults because of degener-
ation of the NMJ.27 The reduction of CAF22 levels after 12week
power training supports CAF22 as a marker of muscle wasting
and the development of sarcopenia. In contrast, a study
evaluating an effect of resistance training in older adults
revealed elevation of CAF levels following 6-weeks of training.28
The aim of the present study was to evaluate agrin as a
marker of muscle wasting in patients with stroke. Because
physical exercise is an effective therapy to prevent muscle
wasting,29 we investigated a cohort of stroke patients in the
early post stroke rehabilitation. We hypothesized that
CAF22 might be a marker of muscle status and function
during recovery after paretic stroke. We evaluated CAF22 in
relation to changes in muscle mass and functional recovery
during early rehabilitation period.
Patients and methods
Study population and enrolment criteria
We studied 123 patients (age ranging from 42 to 98 years)
with conﬁrmed diagnosis of ischaemic or haemorrhagic
stroke. Patients were admitted from October 2011 to August
2013 to neurological rehabilitation centre Brandenburgklinik
Bernau, Germany. Clinical and functional examinations were
performed at admission and at discharge. Within the early
post-stroke hospitalized rehabilitation programme all
patients were on standard medical therapy according to
current guideline recommendations (including antiplatelet
drugs, statins, angiotensin-converting enzyme inhibitors, and
β-blocker). Exclusion criteria for this observational study were
acute and chronic inﬂammatory diseases, acute heart failure
or myocardial infarction, liver cirrhosis, acute and chronic
renal failure and dialysis, immune suppressive therapy, and
history of cancer within the last 5 years. Twenty six healthy
individuals of similar body mass index (BMI) and age were
enrolled used as control group. The research protocol was
approved by the local ethics committee, and written informed
consent was obtained from all subjects.
Assessment of functional capacity and physical
examination
Functional independence was assessed using the Barthel in-
dex (BI) that addresses basic self-care and mobility aspects
Figure 1 Structure and cleavage sites of agrin.
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with a score ranging from 0 to 100, where the lowest score
indicates greater dependency.30 Assessment of physical sta-
tus included following testing: the Rivermead motor assess-
ment gross function subscale (RMA) that scores a range of
physical activities with increasing complexity from turning
over in bed to hop on the affected leg 5 times.31,32 Arm
strength was analysed using the handgrip dynamometer
(Saehan Corporation, Korea). The highest of three handgrip
measurements was used for analysis.
Body composition
Body mass index (BMI) was calculated as a ratio of body
weight and squared height (kg/m2). Body composition was
assessed by bioelectrical impedance analysis (BIA) (QuadScan
4000, Bodystat Limited, UK). The principle of BIA analyses is
based on measurements of whole body resistance (R) and
reactance (Xc) values33 where R reﬂects conductivity through
ionic solutions, and Xc reﬂects dielectric properties of plasma
membrane measured as a phase-shift in current ﬂow at
50Hz. Phase angle of the whole body (ϕ, arc tangent express-
ing a relationship between Xc and R) is understood as
bioimpedance measures of cell membranes of skeletal mus-
cle and as indicator of cellular health.34 BIA measurements
were taken in supine position in standard condition as de-
scribed previously.35
Blood samples
Venous blood samples were obtained under standardized
conditions after overnight fasting and after 15min of supine
resting in a quiet and air conditioned room. Samples were
centrifuged at 3500 rpm for 15min (2000x g), aliquoted and
stored at 80°C until analysis. CAF22 concentrations were
measured using a commercially available enzyme-linked im-
munosorbent assay (ELISA) kit (NTCAF Elisa Kit; Neurotune,
Schieren, Switzerland) as described previously.36 The coefﬁ-
cient of variance of the test is 12.3% maximal deviation for
serum and 5.6% maximal deviation for the used calibrator
in a combined intra- and inter-plate comparison. For the
tested samples, the deviation must have been lower than
20% in each double measurement. The accuracy of the
calibrator curve was >0.98 (Rsqr), and the validated range
of detection was 20 pM to 380 pM. In case of higher CFA
values, the sample was diluted with PBS and remeasured
until the value was within the detection range.
Statistical analysis
All variables were tested for normal distribution using the
Kolmogorov–Smirnov test. All data were presented as mean
values ± standard deviation or as median [interquartile range,
IQR]. Paired Student t-test, unpaired Student t-test, and
Mann–Whitney test were used as appropriate. Chi Square
test was used to assess categorical distribution between
groups. The relationship between variables was analysed by
linear and multiple regression analyses. A value of p< 0.05
was considered statistically signiﬁcant. For statistical analysis,
standard statistical software packages were used (Statview
5.0, SAS Institute, Cary, NC).
Results
Clinical and functional characteristics before and
after rehabilitation
Functional assessments were performed at admission (23
± 17 days post stroke) and at discharge from the rehabilita-
tion centre (49 ± 18 days post stroke).
Baseline characteristics of study population groups are
shown in Table 1. Patients and healthy controls were of
similar age and body mass index (BMI). Fifty-ﬁve per cent of
the stroke patients revealed a 2.2% increase of the lean mass
at discharge, whereas in the rest of the patients revealed a
decline of the body lean mass by 2.6% (Table 2). Physical per-
formance and muscle functional measures were signiﬁcantly
impaired after stroke compared to controls (data shown for
the hand grip strength, Figure 2) and improved during reha-
bilitation as assessed by maximum hand grip strength,
Barthel index, and Rivermead motor assessment (Table 2).
Thus, patients presented better functional performance at
discharge from the rehabilitation centre compared to
admission.
CAF22 plasma level during rehabilitation
At admission, CAF22 serum level was signiﬁcantly elevated
(+26%) in stroke patients compared to controls (p< 0.001,
unpaired t-test; Figure 3A). CAF22 level declined subse-
quently during rehabilitation but remained 17% above the
control group at discharge (p< 0.05; Figure 3A). The mean
change of CAF22 serum level between discharge and admis-
sion was expressed as a change of total CAF22 (Table 1).
CAF22 serum levels were not signiﬁcantly different in females
compared to male patients (Table 1). However, compared to
healthy controls female stroke patients showed 21% higher
CAF22 level at admission (Figure 3B), whereas between male
patients and controls this difference was 56% (Figure 3C). At
discharge, CAF22 was 12% higher in female but still 41%
higher in male patients compared to controls of the same
gender. Thus, CAF22 level rise after stroke seems to be more
pronounced in male than in female patients.
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CAF22 and functional performance
In the linear regression analyses CAF22 levels were associated
with BI (r = 0.2, p< 0.022), RMA score (r = 0.2, p< 0.05), hand
grip strength of the non-paretic arm (r = 0.2, p< 0.05), age
(r = 0.4, p< 0.001), and creatinine levels (r = 0.7, p< 0.001).
In multivariable regression analyses change of CAF22 se-
rum level was independently associated with improvement
of the hand grip strength of the paretic arm, but not in the
non-paretic arm in patients who showed increased muscle
mass during rehabilitation (Table 3B). However, this associa-
tion was not observed in the whole study cohort (Table 3A).
CAF22 levels and phase angle
A strong association between CAF22 level at admission and
phase angle (r =0.351, p< 0.001) was observed in simple
regression analysis. After adjustment for age, creatinine level,
and gender this association remained independently signiﬁ-
cant (Table 4).
Discussion
The major ﬁnding of the study is the elevation and dynamic
change of CAF22 serum levels in patients after acute stroke.
CAF22 serum levels were signiﬁcantly increased in the sub-
acute phase after stroke. During rehabilitation, an incomplete
return of elevated CAF22 levels was observed. CAF22 was
associated with parameters of physical and functional
performance and with bioelectrical impedance phase angle.
Further, an improvement of hand grip strength of the paretic
Table 1 Clinical characteristics of study groups
Parameters Controls n= 26 Patients at admission n=123 Patients at discharge n=123
Age, y 67±8 70±11 70± 11
Gender, f/m [m, %] 17/9 [41] 49/74 [60]*
Stroke ischaemic, n [%] / haemorrhagic, n [%] 106 [86] / 17 [16]
Days after stroke 23± 17 49±18###
CAF22, pMol 95.7±31.8 134.3±52.3*** 118.2±42.7*###
CAF22, pMol, female 102.6±30.7 140.3±51.6** 119.5±35.5###
CAP22, pMol, male 82.7±31.2 130.2±52.7** 117.3±47.1*###
Change of total CAF22, pMol 16.1±30.4
Creatinine, mg/dL 0.79±0.14 0.97±0.31** 0.96±0.33
Sodium, mmol/L 141.5±3.3 140.1±4.4 140.3±2.7
Potassium, mmol/L 4.4± 0.4 4.4±0.4 4.3±0.5
Body mass index, kg/m2 25.6±3.3 27.0±4.9 26.0±5.2
Lean mass, kg 46.9±10.1 51.9±11.7* 51.6±11.3
Fat mass, kg 24.9±6.9 25.0±9.7 23.4±8.8
Phase angle, ϕ 5.7±1.1 5.1±1.0** 5.0± 1.0**
*p< 0.05,
**p< 0.01,
***p< 0.001 vs. controls;
###p< 0.001 vs. admission
Table 2 Parameters of body composition and physical performance at
admission and at discharge from the rehabilitation centre
Parameters
At admission
(n=120)
At discharge
(n=120)
Lean mass increase,
kg, n= 67
50.6±11.8 51.7± 11.7***
Lean mass decrease,
kg, n= 56
53.2±11.7 51.7± 11.4***
Max hand grip
strength paretic arm, kg
15.8±11.6 16.0± 11.7***
Max hand grip strength
nonparetic arm, kg
28.2±11.1 29.6± 11.7***
Barthel Index score 60±22 73± 20***
Rivermead Motor
Assessment score
5.3± 2.0 7.2± 2.2***
***p< 0.001 vs. admission
Figure 2 Hand grip strength of stroke patients compared to healthy con-
trols (***p< 0.001 vs. controls; ###p< 0.001 vs. admission).
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arm during rehabilitation was independently associated with
the reduction of CAF22 serum levels in patients who showed
an increase of muscle mass during rehabilitation.
We observed elevated CAF22 serum levels at admission to
inpatient rehabilitation. CAF22 levels decreased during
4weeks of a rehabilitation programme but were still higher
at discharge compared to healthy subjects. Our ﬁndings are
in line with previous reports showing a reduction of elevated
CAF22 levels after a training programme in a cohort of elder
subjects.27 These authors suggested CAF22 as a potential
marker of age-associated sarcopenia caused by the degener-
ation of the NMJ. In our study patients were admitted to the
rehabilitation hospital 3weeks after stroke. At this time point
patients revealed signiﬁcantly reduced handgrip strength in
parallel to elevated CAF22 serum levels. In addition, our anal-
yses have shown an independent association between reduc-
tion of CAF22 serum levels and improvement of hand grip
strength of the paretic arm in patients with increased muscle
mass during rehabilitation. Decreasing of CAF22 levels after
4weeks of a physical rehabilitation programme might there-
fore suggest termination of the muscle wasting and reactive
NMJs recovery.
Recently, CAF22 has been evaluated as a biomarker of
kidney function. Indeed, agrin is expressed in the kidney
and CAF22 has been related to the damage of the glomerular
basement membrane.37,38 In our study patients with renal
failure as well as with dialysis were excluded. We observed
a strong correlation between CAF22 and creatinine, although
the reduction of the creatinine serum level at discharge was
not signiﬁcant in contrast to the signiﬁcant reduction of the
CAF22 serum levels. Thus, it is not clear to which extent
CAF22 serum levels reﬂect the kidney function in stroke
patients. Yet, a confounder for CAF22 serum levels because
of kidney function could not be excluded and may be seen
as a limitation of the study.
In addition, the existence of several splicing isoforms of
agrin should be considered in the evaluation of CAF22 as a
biomarker for sarcopenia.22,39 Agrin function is highly regu-
lated by alternative splicing and proteolytic processing. Splic-
ing isoforms containing 0 or 4 amino acid inserts at the y
splicing site of the LG2 domain and 0, 8, 11, or 19 (8 + 11)
amino acid inserts at the z splicing site of the LG3 domain
of the C-terminus have been investigated (Figure 1).23,40
The neural agrin containing 4 and 8 amino acid inserts at
the y and z sites, respectively, has a high afﬁnity to the AChR
clustering, while muscle agrin and agrin found in other non-
neuronal cells lacks inserts and fails to cluster AChRs.41 How-
ever, splicing isoforms of agrin lacking inserts have been
found in NMJs (motor neurons, skeletal muscle, and Schwann
cells), in the central nervous system and peripheral tissues
(lung and kidney).23 The ELISA assay used in the present
study predominately identiﬁes the z0 splicing isoform. Previ-
ous experiments have shown that the z0 splicing isoform is
at least 10–20 folds overrepresented over the insert baring
Figure 3 CAF22 plasma level in stroke-patients at admission to rehabili-
tation centre and at discharge compared to controls: All patients (A); Fe-
male patients (B); Male patients (C) (***p< 0.001, **p< 0.01, *p< 0.05
vs. controls;
###
p< 0.001 vs. admission).
B
C
A
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splice isoforms (Western blots and internal analyses). The
appearance of the z0 splicing variant of the C-terminal agrin
fragments in blood, however, represents the activity of
neurotrypsin.42 Further, a vast amount of z0 isoform of agrin
is present on the postsynaptic side, which is also cleavable by
neurotrypsin. Muscle agrin is concentrated at the nerve-
induced AChR clusters where it contributes to maturation
and stabilization of the receptors.43,44 Therefore, the postsyn-
aptic muscle agrin is able to liberate CAF22, which may then
be secreted and may appear in the blood stream. Thus, we
believe that in stroke patients a signiﬁcant amount of the
CAF22 in serum origins from the nervous tissue or postsynap-
tic tissue because of denervation and degradation of the
NMJs. However, optimization of the ELISA assay towards
identifying of the neuronal agrin might improve the speciﬁc-
ity and sensitivity of the results and may contribute to the
establishing of CAF22 as a marker of muscle wasting caused
by NMJ degeneration.
Our analyses revealed an independent association of the
BIA phase angle with CAF22 levels. Phase angle has been
shown in relation to the muscle mass and muscle strength;
therefore phase angle represents a simple index of the
integrity of the skeletal muscle cell membranes.34 A previous
study in patients with neuromuscular diseases has shown a
decline of phase angle in parallel with disease progression
that was accompanied by a subsequent decline of muscle
strength and quality of muscle tissue.45 Therefore our data
suggest lower CAF22 to indicate a better cellular integrity of
muscle tissue.
The present study had same limitations. As mentioned
above, renal function may be a relevant confounder of CAF
22 levels. Further, BIA assessment may provide only limited
information on body composition and more detailed informa-
tion on tissue distribution and composition may be desirable.
Previous studies comparing body composition assessment by
BIA and dual-energy X-ray absorptiometry DEXA, or by BIA
and magnet resonance imaging MRI, conﬁrmed reliable
agreement between these methods.46–50 Another study ex-
amining muscle mass assessed by BIA and MRI indicated a
strong relation between muscle mass and body resistance.49
However, underestimation of the fat mass and over
predicting of the fat-free mass assessed by BIA has been re-
ported.47 In addition, the presence of oedema may inﬂuence
BIA measurements. The effect of the whole body water
changes and its dependence from the sodium plasma concen-
trations has been discussed previously.51 However, in the
Table 3 A). Multiple regression analyses investigating change of hand grip strength during rehabilitation in stroke patients (n = 123)
Parameter Coefﬁcient p r
1. Change of hand grip strength of paretic arm vs. 0.286
Gender 0.059 0.579
Age 0.229 0.035
Change of CAF22 0.175 0.097
Creatinine 0.102 0.353
2. Change of hand grip strength of nonparetic arm vs. 0.294
Gender 0.141 0.151
Age 0.157 0.120
Change of CAF22 0.121 0.223
Creatinine 0.189 0.069
Table 4 Multiple regression analysis investigating phase angle as a pa-
rameter of cell membrane integrity in stroke patients
Parameter Coefﬁcient p r
Phase angle vs. 0.523
Gender 0.170 0.055
Age 0.341 0.0003
Creatinine 0.095 0.422
CAF22 0.267 0.026
Table 3 B.) Multiple regression analyses investigating changes in hand grip strength at discharge and admission in stroke patients with improved lean
mass during rehabilitation (n = 67)
Parameter Coefﬁcient p r
1. Change of hand grip strength of paretic arm vs. 0.318
Gender 0.045 0.749
Age 0.218 0.134
Change of CAF22 0.292 0.045
Creatinine 0.089 0.563
2. Change of hand grip strength of nonparetic arm vs. 0.301
Gender 0.046 0.723
Age 0.100 0.465
Change of CAF22 0.180 0.211
Creatinine 0.293 0.055
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present study patients were free of peripheral oedema and
sodium plasma levels remained unchanged suggesting stable
ﬂuid balance during the observation period.
In conclusion, CAF22 serum levels were elevated in the sub-
acute phase after acute stroke and fell during rehabilitation.
Associations between CAF22 and parameters of physical per-
formance, muscle strength, and muscle membrane integrity
have been observed. In multivariable analysis recovery of
increased CAF22 levels was independently associated with im-
proved hand grip strength only in those patients who showed
increasing lean tissue during rehabilitation but not in the en-
tire cohort. The present data are promising to explore further
the role CAF22 as a potential serum marker for monitoring
muscle status in patients after stroke. Further studies are
warranted including optimization of the analytic assay of
CAF to evaluate the role of CAF22 as a serum marker of
muscle wasting in stroke patients.
Conﬂict of interest
NS, MK, NE, MV, AS, UG, SvH, SDA, UD, MJ, and WD: no con-
ﬂict of interest. PD and SH are employed by Neurotune AG
that develops the CAF biomarker.
Acknowledgements
We thank Mrs. Anja Kresse for her excellent technical assis-
tance with this study. The authors certify that they comply with
the ethical guidelines for authorship and publishing of the
Journal of Cachexia, Sarcopenia and Muscle (von Haehling S,
Morley JE, Coats AJS, Anker SD. Ethical guidelines for authorship
and publishing in the Journal of Cachexia, Sarcopenia and
Muscle. J Cachexia Sarcopenia Muscle. 2010; 1:7–8.)
References
1. Scherbakov N, von Haehling S, Anker SD,
Dirnagl U, Doehner W. Stroke induced
Sarcopenia: muscle wasting and disability
after stroke. Int J Cardiol 2013;170:89–94.
2. Arasaki K, Igarashi O, Ichikawa Y, Machida T,
Shirozu I, Hyodo A, et al. Reduction in the
motor unit number estimate (MUNE) after ce-
rebral infarction. J Neurol Sci 2006;250:27–32.
3. Li X, Shin H, Zhou P, Niu X, Liu J, Rymer WZ.
Power spectral analysis of surface electro-
myography (EMG) at matched contraction
levels of the ﬁrst dorsal interosseous mus-
cle in stroke survivors. Clin Neurophysiol
2014;125:988–994.
4. Harris ML, Polkey MI, Bath PM, Moxham J.
Quadriceps muscle weakness following
acute hemiplegic stroke. Clin Rehabil
2001;15:274–281.
5. Carin-Levy G, Greig C, Young A, Lewis S,
Hannan J, Mead G. Longitudinal changes
in muscle strength and mass after acute
stroke. Cerebrovasc Dis 2006;21:201–207.
6. Jørgensen L, Jacobsen BK. Changes in
muscle mass, fat mass, and bone mineral
content in the legs after stroke: a 1 year
prospective study. Bone 2001;28:655–659.
7. Scherbakov N, Sandek A, DoehnerW. Stroke-
related Sarcopenia: speciﬁc characteristics. J
Am Med Dir Assoc 2015;16:272–276.
8. Springer J, Schust S, Peske K, Tschirner A, Rex
A, Engel O, et al. Catabolic signaling andmus-
cle wasting after acute ischemic stroke in
mice: indication for a stroke-speciﬁc
sarcopenia. Stroke 2014;45:3675–3683.
9. De Deyne PG, Hafer-Macko CE, Ivey FM,
Ryan AS, Macko RF. Muscle molecular phe-
notype after stroke is associated with gait
speed. Muscle Nerve 2004;30:209–215.
10. Scherbakov N, Doehner W. Sarcopenia in
stroke-facts and numbers on muscle loss
accounting for disability after stroke. J Ca-
chexia Sarcopenia Muscle 2011;2:5–8.
11. Rosenberg IH. Sarcopenia: origins and clin-
ical relevance. J Nutr 1997;127:990S–991S.
12. Morley JE, Anker SD, von Haehling S.
Prevalence, incidence, and clinical impact
of sarcopenia: facts, numbers, and
epidemiology—update 2014. J Cachexia
Sarcopenia Muscle 2014;5:253–259.
13. Wakabayashi H, Sakuma K. Rehabilitation
nutrition for sarcopenia with disability: a
combination of both rehabilitation and nu-
trition care management. J Cachexia
Sarcopenia Muscle 2014;5:269–277.
14. Barbat-Artigas S, Dupontgand S, Pion CH,
Feiter-Murphy Y, Aubertin-Leheudre M.
Identifying recreational physical activities
associated with muscle quality in men
and women aged 50 years and over. J Ca-
chexia Sarcopenia Muscle 2014;5:221–228.
15. Muscaritoli M, Anker SD, Argilés J, Aversa
Z, Bauer JM, Biolo G, et al. Consensus def-
inition of sarcopenia, cachexia and pre-
cachexia. Clin Nutr 2010;29:154–159.
16. Fanzani A, Conraads VM, Penna F, Martinet
W. Molecular and cellular mechanisms of
skeletal muscle atrophy: an update. J Ca-
chexia Sarcopenia Muscle 2012;3:163–179.
17. Palus S, von Haehling S, Springer J. Muscle
wasting: an overview of recent develop-
ments in basic research. J Cachexia
Sarcopenia Muscle 2014;5:193–198.
18. Henwood TR, Keogh JW, Reid N, Jordan W,
Senior HE. Assessing sarcopenic prevalence
and risk factors in residential aged care:
methodology and feasibility. J Cachexia
Sarcopenia Muscle 2014;5:229–236.
19. Drey M, Grösch C, Neuwirth C, Bauer JM,
Sieber CC. The Motor Unit Number Index
(MUNIX) in sarcopenic patients. Exp
Gerontol 2013;48:381–384.
20. Alchin DR. Sarcopenia: describing rather
than deﬁning a condition. J Cachexia
Sarcopenia Muscle 2014;5:265–268.
21. Hettwer S, Dahinden P, Kucsera S, Farina C,
Ahmed S, Fariello R, et al. Elevated levels
of a C-terminal agrin fragment identiﬁes a
new subset of sarcopenia patients. Exp
Gerontol 2013;48:69–75.
22. Bezakova G, Ruegg MA. New insights into
the roles of agrin. Nat Rev Mol Cell Biol
2003;4:295–308.
23. Ruegg MA, Bixby JL. Agrin orchestrates syn-
aptic differentiation at the vertebrate neu-
romuscular junction. Trends Neurosci
1998;21:22–27.
24. Ferraro E, Molinari F, Berghella L. Molecu-
lar control of neuromuscular junction de-
velopment. J Cachexia Sarcopenia Muscle
2012;3:13–23.
25. Zong Y, Jin R. Structural mechanisms of the
agrin–LRP4–MuSK signaling pathway in
neuromuscular junction differentiation.
Cell Mol Life Sci 2013;70:3077–3088.
26. Bütikofer L, Zurlinden A, Bolliger MF, Kunz
B, Sonderegger P. Destabilization of the
neuromuscular junction by proteolytic
cleavage of agrin results in precocious
sarcopenia. FASEB J 2011;25:4378–4393.
27. Drey M, Sieber CC, Bauer JM, Uter W,
Dahinden P, Fariello RG, Vrijbloed JW,
FiAT intervention group. C-terminal Agrin
Fragment as a potential marker for
sarcopenia caused by degeneration of
the neuromuscular junction. Exp Gerontol
2013;48:76–80.
28. Fragala MS, Jajtner AR, Beyer KS, Townsend
JR, Emerson NS, Scanlon TC, Oliveira LP,
Hoffman JR, Stout JR. Biomarkers of muscle
quality: N-terminal propeptide of type III
procollagen and C-terminal agrin fragment
responses to resistance exercise training in
older adults.. J Cachexia Sarcopenia Muscle
2014;5:139–148.
29. Rhee CM, Kalantar-Zadeh K. Resistance exer-
cise: an effective strategy to reverse muscle
66 N. Scherbakov et al.
Journal of Cachexia, Sarcopenia and Muscle 2016; 7: 60–67
DOI: 10.1002/jcsm.12068
wasting in hemodialysis patients? J Cachexia
Sarcopenia Muscle 2014;5:177–180.
30. Kasner SE. Clinical interpretation and use of
stroke scales. Lancet Neurol 2006;5:603–612.
31. Lincoln N, Leadbitter D. Assessment of mo-
tor function in stroke patients. Physiother-
apy 1979;65:48–51.
32. Collen FM, Wade DT, Robb GF, Bradshaw
CM. The Rivermead Mobility Index: a fur-
ther development of the Rivermead Motor
Assessment. Int Disabil Stud 1991;13:50–54.
33. Kushner RF. Bioelectrical impedance analy-
sis: a review of principles and applications.
J Am Coll Nutr 1992;11:199–209.
34. Selberg O, Selberg D. Norms and correlates
of bioimpedance phase angle in healthy
human subjects, hospitalized patients, and
patients with liver cirrhosis. Eur J Appl
Physiol 2002;86:509–516.
35. Lukaski HC, Johnson PE, Bolonchuk WW,
Lykken GI. Assessment of fat-free mass
using bioelectrical impedance measure-
ments of the human body. Am J Clin Nutr
1985;41:810–817.
36. http://www.neurotune.com/tl_ﬁles/
neurotune/pdf/NTCAF_ELISA_Manual.pdf
37. Steubl D, Hettwer S, Vrijbloed W, Dahinden
P, Wolf P, Luppa P, et al. C-terminal agrin
fragment—a new fast biomarker for kidney
function in renal transplant recipients. Am
J Nephrol 2013;38:501–508.
38. Steubl D, Hettwer S, Dahinden P, Wolf P,
Luppa P, Wagner CA, et al. Inﬂuence of
high-ﬂux hemodialysis and hemodiaﬁltration
on serum C-terminal agrin fragment levels in
end-stage renal disease patients. Transl Res
2014;164:392–399.
39. Drey M, Behnes M, Kob R, Lepiorz D,
Hettwer S, Bollheimer C, et al. C-Terminal
Agrin Fragment (CAF) reﬂects renal func-
tion in patients suffering from severe
sepsis or septic shock. Clin Lab
2015;61:69–76.
40. Ferns MJ, Campanelli JT, Hoch W, Scheller
RH, Hall Z. The ability of agrin to cluster
AChRs depends on alternative splicing and
on cell surface proteoglycans. Neuron
1993;11:491–502.
41. Bezakova G, Helm JP, Francolini M, Lømo T.
Effects of puriﬁed recombinant neural and
muscle agrin on skeletal muscle ﬁbers
in vivo. J Cell Biol 2001;153:1441–1452.
42. Bolliger MF, Zurlinden A, Lüscher D,
Bütikofer L, Shakhova O, Francolini M,
et al., Kunz B, Sonderegger P. Speciﬁc pro-
teolytic cleavage of agrin regulates matura-
tion of the neuromuscular junction. J Cell
Sci 2010;123:3944–3955.
43. Lieth E, Fallon JR. Muscle agrin: neural reg-
ulation and localization at nerve-induced
acetylcholine receptor clusters. J Neurosci
1993;13:2509–2514.
44. Fumagalli G, Balbi S, Cangiano A, Lømo T.
Regulation of turnover and number of ace-
tylcholine receptors at neuromuscular
junctions. Neuron 1990;4:563–569.
45. Rutkove SB, Aaron R, Shiffman CA. Local-
ized bioimpedance analysis in the
evaluation of neuromuscular disease. Mus-
cle Nerve 2002;25:390–397.
46. Kafri MW, Potter JF, Myint PK. Multi-
frequency bioelectrical impedance analysis
for assessing fat mass and fat-free mass in
stroke or transient ischaemic attack
patients. Eur J Clin Nutr 2014;68:677–682.
47. Treviño-Aguirre E, López-Teros T, Gutiérrez-
Robledo L, Vandewoude M, Pérez-Zepeda
M. Availability and use of dual energy
X-ray absorptiometry (DXA) and bio-
impedance analysis (BIA) for the evaluation
of sarcopenia by Belgian and Latin
American geriatricians. J Cachexia
Sarcopenia Muscle 2014;5:79–81.
48. Pateyjohns IR, Brinkworth GD, Buckley JD,
Noakes M, Clifton PM. Comparison of
three bioelectrical impedance methods
with DXA in overweight and obese men.
Obesity (Silver Spring) 2006;14:2064–2070.
49. Janssen I, Heymsﬁeld SB, Baumgartner RN,
Ross R. Estimation of skeletal muscle mass
by bioelectrical impedance analysis. J Appl
Physiol (1985) 2000;89:465–471.
50. Heymsﬁeld SB, Adamek M, Gonzalez MC,
Jia G, Thomas DM. Assessing skeletal mus-
cle mass: historical overview and state of
the art. J Cachexia Sarcopenia Muscle
2014;5:9–18.
51. Berneis K, Keller U. Bioelectrical imped-
ance analysis during acute changes of
extracellular osmolality in man. Clin Nutr
2000;19:361–366.
CAF as a marker of muscle wasting after stroke 67
Journal of Cachexia, Sarcopenia and Muscle 2016; 7: 60–67
DOI: 10.1002/jcsm.12068
